Utilizing our wide range of services with a UNIQUE HIGH THROUGHPUT PHARMACOLOGY APPROACH:

» in-vivo efficacy
» pharmacokinetics
» indications discovery
» specialized models
» bioanalytical services

melior (mēl’ər) v. To make better; improve.
Melior Discovery Inc (Exton, PA, USA) has pioneered a unique “high throughput” in vivo pharmacology platform (theraTRACE®) able to systematically identify novel indications for pre-clinical and development stage drugs. theraTRACE®is widely used by both multinational pharmaceutical and start-up biopharmaceutical companies alike to fully explore the therapeutic potential of their drug candidates.

Melior has also leveraged this expertise to build a high quality, onshore, preclinical services capability offering in vivo efficacy models in a broad range of therapeutic areas, pharmacokinetic evaluations, specialized animal models and bioanalytical services to drug developers worldwide.

**In Vivo Pharmacology Experience**

Melior’s management has combined experience of more than 120 years in pharmacology and drug discovery applications and has evaluated more than 200 compounds for novel indications in just 3 years. The company has long-term collaborations with Pfizer, Merk, AstraZeneca, Johnson and Johnson, amongst others major partners.

**Uniquely Productive Drug Discovery Strategy**

The therarACE® indications discovery platform allows for known drug-like compounds to be comprehensively screened using a battery of in vivo assays spanning multiple therapeutic areas. Currently over 40 validated animal models are represented in the platform spanning a broad range of therapeutic areas including inflammation, immunology, diabetes & metabolic syndrome, dermatology, cardiovascular, gastrointestinal, psychiatric, neurological and neurodegenerative disorders. The in vivo models utilized in the therarACE® platform comprise those typically used by pharmaceutical companies to determine whether a drug candidate is suitable for further clinical evaluation, however, these models are assembled in a proprietary “multiplexed” format that allows drug discoverers to evaluate a compound for potential efficacy in a broad array of therapeutic areas rapidly and cost-effectively. In most cases, Melior’s therarACE® system is able to provide a complete pharmacological fingerprint/profile of a compound in 10 weeks. Melior’s therarACE® system has found particular utility in facilitating the crucial “go/no go” development decisions routinely faced by pharmaceutical and biopharmaceutical companies.

**Focused Disease Efficacy Models**

In addition to the therarACE® indications discovery platform and a proprietary Alzheimer’s disease model, Melior is able to extend its high throughput pharmacology approach to customized in vivo efficacy evaluations in other focused therapeutic areas.

**PK and Bioanalytical Capabilities**

An effective drug must remain at the site of action long enough have the desired pharmacological effect. Early evaluation of the ability of a compound to move from the dosing site to the target site is an essential step in drug development.

Melior offers a set comprehensive in vivo rodent PK models, ranging from a rapid PK screening service to multi-group custom PK study designs that are integral to the interpretation of drug properties and the ability to relate these to optimum dosing paradigms.

Bioanalytical testing provides quantitative measurement of an active drug and/or its metabolites in biological matrices (plasma, brain tissue, urine etc.). Custom specific and sensitive bioanalytical methods are required to make these measurements. Melior’s bioanalytical lab employs state-of-the-art highthroughput LC/MS/MS equipment to offer the most sensitive bioanalytical method possible.

Our highly consultative approach to contract research has enabled our team to bring their expertise in strategy and protocol design to each client according to their specific needs. All of Melior’s preclinical services are conducted in state-of-the-art laboratory facilities located in Exton, Pennsylvania, USA.

**Is There a Shortcut to Drug Development Success?**

Melior Discovery Inc (Exton, PA, USA) has pioneered a unique “high throughput” in vivo pharmacology platform (theraTRACE®) able to systematically identify novel indications for pre-clinical and development stage drugs. therarACE®is widely used by both multinational pharmaceutical and start-up biopharmaceutical companies alike to fully explore the therapeutic potential of their drug candidates.

Melior has also leveraged this expertise to build a high quality, onshore, preclinical services capability offering in vivo efficacy models in a broad range of therapeutic areas, pharmacokinetic evaluations, specialized animal models and bioanalytical services to drug developers worldwide.

**Melior has established expertise in the following major therapeutic areas:**

- Central Nervous System (including Neurodegenerative diseases and Psychiatry)
- Inflammation (including Allergy, Arthritis and Asthma)
- Acute and chronic pain
- Metabolic diseases
- Gastrointestinal and urology
- Cardiovascular diseases
- Dermatology

In Vivo Pharmacology Experience

Melior’s management has combined experience of more than 120 years in pharmacology and drug discovery applications and has evaluated more than 200 compounds for novel indications in just 3 years. The company has long-term collaborations with Pfizer, Merk, AstraZeneca, Johnson and Johnson, amongst others major partners.

**Melior’s In Vivo Pharmacology Experience**

In Vivo Pharmacology Experience

Melior's In Vivo Pharmacology Experience

Melior’s In Vivo Pharmacology Experience

Melior has established expertise in the following major therapeutic areas:
Melior Discovery Inc (Exton, PA, USA) has pioneered a unique “high throughput” in vivo pharmacology platform (theraTRACE®) able to systematically identify novel indications for pre-clinical and development stage drugs. therarTRACE® is widely used by both multinational pharmaceutical and start-up biopharmaceutical companies alike to fully explore the therapeutic potential of their drug candidates.

Melior has also leveraged this expertise to build a high quality, onshore, preclinical services capability offering in vivo efficacy models in a broad range of therapeutic areas, pharmacokinetic evaluations, specialized animal models and bioanalytical services to drug developers worldwide.

Uniquely Productive Drug Discovery Strategy

The therarTRACE® indications discovery platform allows for known drug-like compounds to be comprehensively screened using a battery of in vivo assays spanning multiple therapeutic areas. Currently over 40 validated animal models are represented in the platform spanning a broad range of therapeutic areas including inflammation, immunology, diabetes & metabolic syndrome, dermatology, cardiovascular, gastrointestinal, psychiatric, neurological and neurodegenerative disorders. The in vivo models utilized in the therarTRACE® platform comprise those typically used by pharmaceutical companies to determine whether a drug candidate is suitable for further clinical evaluation, however, these models are assembled in a proprietary “multiplexed” format that allows drug discoverers to evaluate a compound for potential efficacy in a broad array of therapeutic areas rapidly and cost-effectively. In most cases, Melior’s therarTRACE® system is able to provide a complete pharmacological fingerprint/profile of a compound in 10 weeks. Melior’s therarTRACE® system has found particular utility in facilitating the crucial “go/no go” development decisions routinely faced by pharmaceutical and biopharmaceutical companies.

Focused Disease Efficacy Models

In addition to the therarTRACE® indications discovery platform and a proprietary Alzheimer’s disease model, Melior is able to extend its high throughput pharmacology approach to customized in vivo efficacy evaluations in other focused therapeutic areas.

Melior’s In Vivo Pharmacology Experience

Melior’s management has combined experience of more than 120 years in pharmacology and drug discovery applications and has evaluated more than 200 compounds for novel indications in just 3 years. The company has long-term collaborations with Pfizer, Merck, AstraZeneca, Johnson and Johnson, amongst others major partners.

Melior has established expertise in the following major therapeutic areas:

- Central Nervous System (including Neurodegenerative diseases and Psychiatry)
- Inflammation (including Allergy, Arthritis and Asthma)
- Acute and chronic pain
- Metabolic diseases
- Gastrointestinal and urology
- Cardiovascular diseases
- Dermatology

Melior Announces the Availability of an Exclusive Model for Alzheimer’s Disease

Available murine models of Alzheimer’s disease rely solely upon the super normal expression of amyloid precursor protein (APP) which is not predictive of the human condition. In addition, available models exhibit exponential plaque deposition kinetics which may confound efforts to identify drug candidate efficacy. Melior’s proprietary huAB mouse model is capable of reliably and predictably assessing plaque deposition relevant to the progression of human Alzheimer’s disease. Melior’s neuroTRACE® platform provides the addition of Melior Discovery’s complementary behavioral models, so that improvement of cognitive deficits in Alzheimer’s disease can be effectively evaluated.

In Vivo PK and Bioanalytical Capabilities

An effective drug must remain at the site of action long enough have the desired pharmacological effect. Early evaluation of the ability of a compound to move from the dosing site to the target site is an essential step in drug development.

Melior offers a set comprehensive in vivo rodent PK models, ranging from a rapid PK screening service to multi-group custom PK study designs that are integral to the interpretation of drug properties and the ability to relate these to optimum dosing paradigms.

Bioanalytical testing provides quantitative measurement of an active drug and/or its metabolites in biological matrices (plasma, brain tissue, urine etc.). Custom specific and sensitive bioanalytical methods are required to make these measurements. Melior’s bioanalytical lab employs state-of-the-art highthroughput LC/MS/MS equipment to offer the most sensitive bioanalytical method possible.

Our highly consultative approach to contract research has enabled our team to bring their expertise in strategy and protocol design to each client according to their specific needs. All of Melior’s preclinical services are conducted in state-of-the-art laboratory facilities located in Exton, Pennsylvania, USA.
Utilizing our wide range of services with a
UNIQUE HIGH THROUGHPUT
PHARMACOLOGY APPROACH:

» in-vivo efficacy
» pharmacokinetics
» indications discovery
» specialized models
» bioanalytical services